Table 2.
Top 10 predicted targets of sorafenib
| Target | Scorepositive | Scorenegative | Scorepositive − Scorenegative | Docking score | Significance measure |
|---|---|---|---|---|---|
| PDE4B | 0.69 | 0.83 | −0.14 | −167.63 | <1% |
| SRC | 0.70 | 1.17 | −0.47 | −92.22 | 2% |
| HLA-B | 0.67 | 0.86 | −0.19 | −85.80 | 2% |
| HLA-A | 0.69 | 0.75 | −0.06 | −73.87 | 3% |
| MAPK1 | 0.65 | 0.99 | −0.34 | −72.66 | 4% |
| MAPKAPK2 | 0.64 | 0.86 | −0.22 | −50.03 | 9% |
| QPRT | 0.65 | 0.76 | −0.11 | −40.77 | 9% |
| FLG | 0.7 | 0.72 | −0.02 | −23.11 | 11% |
| FECH | 0.68 | 0.9 | −0.22 | −13.99 | 14% |
| PKCη | 0.58 | 0.78 | −0.20 | −11.71 | 14% |
Note: The predicted targets have less than 60% sequence similarity with the known targets of sorafenib. Proteins that do not contain a kinase domain are shown in bold. PDE4B, cAMP-specific 3ʹ,5ʹ-cyclic phosphodiesterase 4B; SRC, proto-oncogene tyrosine-protein kinase Src; HLA-B, human leukocyte antigen B (57:01.I80T); HLA-A, human leukocyte antigen A (02:03); MAPK1, mitogen-activated protein kinase 1; MAPKAPK2, mitogen-activated protein kinase-activated protein kinase 2; QPRT, nicotinate-nucleotide pyrophosphorylase; FLG, filaggrin; FECH, ferrochelatase, mitochondrial; PKCη, protein kinase C eta type.